Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 16/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615312 | 1.00 | EZH2 (0.33) | EZH2HTR2CSLC6A4 | |
| SCHEMBL13225935 | 1.00 | EZH2 (0.33) | EZH2HTR2CSLC6A4 | |
| SCHEMBL4943670 | 0.94 | EZH2 (0.33) | EZH2HTR2CSLC6A4 | |
| SCHEMBL4943648 | 0.94 | EZH2 (0.33) | EZH2HTR2CSLC6A4 | |
| SCHEMBL4492829 | 0.81 | AKR1B1 (0.35) | EZH2 | |
| SCHEMBL14007689 | 0.79 | HTR2C (0.30) | HTR2CSLC6A4 | |
| SCHEMBL3023303 | 0.78 | EZH2 (0.32) | EZH2 | |
| SCHEMBL1336823 | 0.78 | EZH2 (0.32) | EZH2 | |
| SCHEMBL14007687 | 0.78 | HTR2C (0.31) | HTR2CSLC6A4 | |
| SCHEMBL1336948 | 0.77 | AKR1B1 (0.38) | EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216834-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-08-26 | — | — | US | disclosed |
| US-20100216834-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-08-26 | — | — | US | disclosed |
| EP-2084160-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080280945-A1 | Crystalline forms of an HIV integrase inhibitor | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-20080280945-A1 | Crystalline forms of an HIV integrase inhibitor | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-20080280945-A1 | Crystalline forms of an HIV integrase inhibitor | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| WO-2008048538-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008048538-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216834-A1 | HIV INTEGRASE INHIBITORS | REV1, CDK9, INTS9 | EZH2 1456/4885HTR2C 4150/4885SLC6A4 2800/4885 |
| US-20080280945-A1 | Crystalline forms of an HIV integrase inhibitor | TYMP, SAMHD1, ACIN1 | EZH2 3779/4885HTR2C 3257/4885SLC6A4 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.